Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN) (SévoRein)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00337051
Recruitment Status : Completed
First Posted : June 15, 2006
Last Update Posted : June 23, 2010
Ministry of Health, France
Information provided by:
University Hospital, Bordeaux

Brief Summary:

Renal transplantation is characterized by ischemia-reperfusion lesions in allograft. In a previous study, Julier and al. (Anesthesiology 2003) have demonstrated that sevoflurane reduces glomerular lesions in kidney of patients undergoing a cardiovascular surgery and présenting with ischemia-reperfusion phenomena.

The purpose of the study is to evaluate the effects of sevoflurane on the recovery of renal graft function in patients after kidney transplantation.

This study will be a randomized, double blinded, controlled clinical trial and 120 patients undergoing renal allograft transplantation will be included.

Patients will be divided into 2 groups: one group of patients who will receive sevoflurane (evaluated treatment) for anaesthesia and the other one who will receive propofol (reference treatment).

We will evaluate renal function for one year after transplantation. Ours results will confirm or not that sevoflurane protects kidney function from ischemia-reperfusion lesions.

Condition or disease Intervention/treatment Phase
End-stage Chronic Renal Disease Severe Acute Kidney Failure Renal Transplantation Drug: Sevoflurane Drug: Propofol Phase 3

  Hide Detailed Description

Detailed Description:

Introduction :

Renal transplantation is characterized by ischemia-reperfusion lesions in allografts. Prolonged cold ischemia duration, age of donor (older than 50) or donor cardiac arrest are common factors associated with delayed graft function. In cardiac surgery, Sevoflurane (a volatile-inhaled anesthetic) protects the heart from ischemia-reperfusion lesions and preserves glomerular filtration function in patients. This cardioprotective effect involves K+-ATP mitochondrial channels which are also known to be expressed in renal cells.

Therefore, it is interesting to evaluate Sevoflurane effects in the context of renal allograft transplantation in order to shorten the delayed graft function and enhance post-operative renal function


Main goal:

Evaluate time necessary to obtain serum creatinine levels inferior to 200µmol/l of the recipient in the group receiving Sevoflurane in comparison with the group of patients receiving propofol infusion for general anaesthesia

Secondary goals:

  • Compare serum creatinine levels in the two groups at day14
  • Compare patient survival and acute rejection occurrence over a period of one-year follow-up in the two groups
  • Compare the safety of both anesthetics assessed as renal tubular injury-toxicity (by measuring serum levels of NAG) and levels of serum inorganic fluor products in the post-operative period; and by referencing all adverse events
  • Compare the effect of both anesthetics on delayed-recovery graft function by assessing clinical end-points (daily diuresis, number of haemodialysis sessions in the two weeks following transplantation) and biological end-points (serum creatinin and cystatinC levels in the two weeks following transplantation)


120 patients scheduled to undergo a renal allograft transplantation with transplants defined by either a cold ischemia duration of more than 20h or a donor's age older than 50 years or a donor cardiac arrest will be randomized in 2 groups of sixty patients undergoing two different general anesthesia protocols. All patients will be included in the Renal Transplantation Unit of Bordeaux University Hospital, Aquitaine, France.


This study will be a clinical randomized trial on 2 parallel groups. It will be double-blind for nephrologists and biologists who evaluate the end-points and will involve a population of renal transplanted patients.

The study will compare clinical and biological outcomes according to the type of general anesthesia undergone for transplantation:

  • One group of patients with inhaled anesthesia by Sevoflurane (evaluated treatment)
  • One group of patients with intravenous anesthesia by propofol (reference treatment).

Patients will be evaluated over a period of one year follow-up. This study is multicentric, based in Aquitaine for a period of three years, involving anaesthesiologists, nephrologists, and urologists.

Baseline brain-dead donor and graft donation characteristics will be collected by the Hospital Coordination team in Bordeaux, Pau and Bayonne.

Statistical analysis will be on intention-to-treat basis. Expected results: 1-Demonstrate Sevoflurane benefit for ischemia-reperfusion protection in renal allograft and a shortened recovery of renal graft function in the two-week post-operative period in the group allocated for Sevoflurane exposure during anaesthesia. 2-Confirm the good safety of Sevoflurane exposure in chronic end-stage renal diseased patients undergoing renal transplantation.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sevoflurane-induced Prevention of Ischemia-reperfusion Lesions in Renal Allograft Transplants Recipients
Study Start Date : June 2006
Actual Primary Completion Date : February 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: S
General Anesthesia with sevoflurane (inhalation) as hypnotic
Drug: Sevoflurane
General anesthesia using Sevoflurane (inhalation) as hypnotic
Active Comparator: P
General Anesthesia With Propofol TCI
Drug: Propofol
General anesthesia with propofol TCI

Primary Outcome Measures :
  1. time to obtain serum creatinine levels inferior to 200µmol/l in the transplant recipient [ Time Frame: evalued at 14 days ]

Secondary Outcome Measures :
  1. creatinemia levels at day 14 [ Time Frame: evalued at 14 days ]
  2. patient survival [ Time Frame: during 1 year follow-up ]
  3. acute rejection occurrence [ Time Frame: during 1 year follow-up ]
  4. safety : renal tubular injury toxicity (serum cystatinC and NAG), serum inorganic fluor products [ Time Frame: 1, 2 and 3 days after kidney transplantation ]
  5. other clinical end-points: daily diuresis, number of haemodialysis sessions [ Time Frame: during the two weeks following transplantation ]
  6. other biological end-points: serum creatinin and cystatinC levels [ Time Frame: during the two weeks following transplantation ]
  7. Other adverse events [ Time Frame: during one year folow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 18 years
  • scheduled to undergo renal allograft transplantation
  • transplant : cold ischemia duration > 20 hours or donor age > 50 years or donor cardiac arrest
  • ASA 2-3
  • social security affiliation
  • informed consent signed

Exclusion Criteria:

  • halogenated anesthetic agent hypersensibility
  • medical history or familial history of malignant hyperthermia
  • porphyria
  • pregnancy or breast feeding
  • hyperimmunized patient
  • participation in an immunosuppressive drug trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00337051

Département d'anesthésie réanimation 1 - Hôpital Pellegrin - CHU de Bordeaux
Bordeaux, France, 33076
Sponsors and Collaborators
University Hospital, Bordeaux
Ministry of Health, France
Principal Investigator: Francois SZTARK, Pr University Hospital, Bordeaux
Study Chair: Paul PEREZ, Dr University Hospital, Bordeaux

Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux Identifier: NCT00337051     History of Changes
Other Study ID Numbers: 9413-04
First Posted: June 15, 2006    Key Record Dates
Last Update Posted: June 23, 2010
Last Verified: June 2010

Keywords provided by University Hospital, Bordeaux:
Renal transplantation
renal allograft
end-stage renal disease
renal failure
general anaesthesia
inhaled anaesthetic
ischemic lesions

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Acute Kidney Injury
Urologic Diseases
Central Nervous System Depressants
Physiological Effects of Drugs
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Platelet Aggregation Inhibitors
Anesthetics, Inhalation